A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

To join this study, you need to be 18 years or older and have a type of non-Hodgkin lymphoma that has either come back or not responded to at least two previous treatments. Your lymphoma must also be measurable, meaning doctors can clearly see and track it with scans. Women taking part in the study must agree to use effective contraception to prevent pregnancy.

There are certain reasons why you might not be able to join. For example, if your general health and how well you can go about your daily activities are not at a certain level, or if you've had specific other treatments recently, such as particular types of stem cell transplants, radiotherapy, or CAR-T cell therapy within a certain timeframe before the study starts. You also wouldn't be able to join if you have certain other medical conditions or an inability to follow all the study's rules and restrictions, for your safety.

If you decide to take part in this study, you would first undergo a screening process to see if you meet all the requirements. This would involve various tests and assessments. Once enrolled, you would receive the study treatment, which could be BMS-986458 on its own or in combination with other anti-lymphoma drugs (Rituximab, Glofitamab/Obinutuzumab, or Mosunetuzumab). You would have regular hospital visits for medical checks, blood tests, and scans to monitor your health and how the treatment is affecting your lymphoma. The specific schedule and total duration of your participation would depend on which part of the study you are in and your individual response to treatment. You would be fully informed about all visit schedules and commitments before making a decision.